RECENT COMMENTS

Vadim I. Shapoval: Oncopatients die because doctors use harmful ineffective antitumor drugs and methods. However, these [...]   »Read more

Kathy Redmond: Readers may have noticed that ESO has deleted a number of comments on this article. This is because [...]   »Read more

Pongsri (Sex and cancer): I teach body image and sexuality in cancer survivors for specialty 4 month cancer nurse program. Thi [...]   »Read more

DR Jennifer L Scott (Sex and cancer): Togehter with my colleague Prof Karen Kayser I have published a review of RCT of interventions to en [...]   »Read more

Dr O. Abimbola Oluwatosin (Sex and cancer): I teach sexuality in Nursing at post graduate level. This article is very useful and will be added t [...]   »Read more

Next issue

Number 38 September - October 2010

Number 38 September - October 2010

» [Editorial] Is it safe, is it tolerable? Why not ask the patients?


 


e-ESO.net

E-eso

Online educational resources Including e-grandrounds, weekly online meetings in collaboration with Nature Reviews Clinical Oncology - CME accredited!

Next live sessions:

GR114 - Do small node negative HER-2 positive tumors deserve a better treatment?

GR115 - Standard management of patients with chronic myeloid leukemia in the era of tirosine kinase inhibitors

GR116 - Survivorship issues and breast cancer

The website is supported by an unrestricted educational grant provided by:

Founding sponsor

CancerWorld invites you to visit:

E-eso
European School of Oncology -
ESO Established in 1982, a non-profit organisation exclusively dedicated to increasing the knowledge of health professionals in cancer care.
E-aso
Euro-Arab School of Oncology - is a joint initiative between the Egyptian Ministry of Health and Population and ESO. EASO intends to enhance and support education in the oncology field in all the Arab countries.
 
ECPC
ECPC
Europa Donna
Europa
Donna
Europa Uomo
Europa
Uomo
EONS
EONS
SIOG
SIOG
The challenge Fund
The
Challenge
Fund
Seno network
SenoNetwork
CancerWorld is a pioneering initiative of the European School of Oncology financially supported through Sharing Progress in Cancer Care, a collaborative programme between ESO and Amgen, AstraZeneca, Eisai, Eli Lilly, Genomic Health, GlaxoSmithKline, Merck and Novartis.